Skip to content
Facebook Instagram Linkedin

LifeScienceHistory.com

History made daily

  • Home
  • DirectoryExpand
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • CareersExpand
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a RockExpand
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
LifeScienceHistory.com
History made daily
Home / Biotechnology - Page 40

Biotechnology

Trial of potential universal flu vaccine opened at NIH Clinical Center
Biotechnology | Infectious Disease | Influenza | NIH | Vaccine

Trial of potential universal flu vaccine opened at NIH Clinical Center

On Jun. 28, 2022, the National Institutes of Health (NIH) announced that a Phase 1 clinical trial of…

Read More Trial of potential universal flu vaccine opened at NIH Clinical CenterContinue

COVID-19 Wheel of Fortune
Biotechnology | Cartoons - Original | COVID-19 | Diagnostics | Disease | FDA | Life Science History | Medicine | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine

COVID-19 Wheel of Fortune

Play the COVID-19 Wheel of Fortune and see how lucky you are! You have two wheels to choose…

Read More COVID-19 Wheel of FortuneContinue

Novavax filed supplement to a New Drug submission in Canada for Nuvaxovid COVID-19 vaccine for adolescents
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Novavax filed supplement to a New Drug submission in Canada for Nuvaxovid COVID-19 vaccine for adolescents

On Jun. 23 2022, Novavax announced the filing of a Supplement to a New Drug Submission with Health…

Read More Novavax filed supplement to a New Drug submission in Canada for Nuvaxovid COVID-19 vaccine for adolescentsContinue

Novavax COVID-19 vaccine Nuvaxovid recommended for expanded conditional marketing authorization in EU for adolescents aged 12 through 17
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Novavax COVID-19 vaccine Nuvaxovid recommended for expanded conditional marketing authorization in EU for adolescents aged 12 through 17

On Jun. 23 2022, Novavax announced that the Nuvaxovid (NVX-CoV2373) COVID-19 vaccine had been recommended for expanded conditional…

Read More Novavax COVID-19 vaccine Nuvaxovid recommended for expanded conditional marketing authorization in EU for adolescents aged 12 through 17Continue

Novavax COVID-19 vaccine Nuvaxovid received EUA in Taiwan for use in individuals aged 18 and over
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Novavax COVID-19 vaccine Nuvaxovid received EUA in Taiwan for use in individuals aged 18 and over

On Jun. 23 2022, Novavax announced that the Taiwan Food and Drug Administration had granted emergency use authorization…

Read More Novavax COVID-19 vaccine Nuvaxovid received EUA in Taiwan for use in individuals aged 18 and overContinue

Innovation Pharmaceuticals reported Brilacidin inhibited Omicron, Delta, Gamma and Alpha SARS-CoV-2 variants
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Therapeutics | Vaccine

Innovation Pharmaceuticals reported Brilacidin inhibited Omicron, Delta, Gamma and Alpha SARS-CoV-2 variants

On Jun. 23, 2022, Innovation Pharmaceuticals reported that Brilacidin, the Company’s defensin-mimetic drug candidate exhibiting broad-spectrum antiviral activity,…

Read More Innovation Pharmaceuticals reported Brilacidin inhibited Omicron, Delta, Gamma and Alpha SARS-CoV-2 variantsContinue

U.S. FDA approved Merck’s VAXNEUVANCE for prevention of invasive pneumococcal disease in infants and children
Biotechnology | FDA | Infectious Disease | Vaccine

U.S. FDA approved Merck’s VAXNEUVANCE for prevention of invasive pneumococcal disease in infants and children

On Jun. 22, 2022, Merck announced that that the U.S. Food and Drug Administration (FDA) had approved an…

Read More U.S. FDA approved Merck’s VAXNEUVANCE for prevention of invasive pneumococcal disease in infants and childrenContinue

Anixa Biosciences Announced Publication of Peer-Reviewed Journal Article Highlighting Ovarian Cancer Vaccine Technology
Biotechnology | Diagnostics | Disease | Oncology | Vaccine | Women's Health

Anixa Biosciences Announced Publication of Peer-Reviewed Journal Article Highlighting Ovarian Cancer Vaccine Technology

On Jun. 21, 2022, Anixa Biosciences announced the publication of a peer-reviewed journal article in Clinical and Experimental…

Read More Anixa Biosciences Announced Publication of Peer-Reviewed Journal Article Highlighting Ovarian Cancer Vaccine TechnologyContinue

Moderna received FDA authorization for EUA of Its COVID-19 vaccine for children 6 months of age and older
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Moderna received FDA authorization for EUA of Its COVID-19 vaccine for children 6 months of age and older

On Jun. 17, 2022, Moderna announced that it had received emergency use authorization from the U.S. Food and…

Read More Moderna received FDA authorization for EUA of Its COVID-19 vaccine for children 6 months of age and olderContinue

Benaroya Research Institute received $11.4 million to explore link between viruses and immune system diseases
Biotechnology | Diagnostics | Non-Profit Research | Therapeutics

Benaroya Research Institute received $11.4 million to explore link between viruses and immune system diseases

On Jun. 17, 2022, Benaroya Research Institute at Virginia Mason (BRI) announced a 5-year, $11.4 million grant from…

Read More Benaroya Research Institute received $11.4 million to explore link between viruses and immune system diseasesContinue

Oragenics announced publication of positive data for NT-CoV2-1 intranasal COVID-19 vaccine candidate in Scientific Reports
Biotechnology | Therapeutics | Vaccine

Oragenics announced publication of positive data for NT-CoV2-1 intranasal COVID-19 vaccine candidate in Scientific Reports

On Jun. 14 2022, Oragenics announced the publication of an article co-authored by Oragenics and collaborators at Inspirevax…

Read More Oragenics announced publication of positive data for NT-CoV2-1 intranasal COVID-19 vaccine candidate in Scientific ReportsContinue

Pfizer reported additional data on PAXLOVID supporting New Drug Application submission to U.S. FDA
Biotechnology | COVID-19 | Infectious Disease | Therapeutics

Pfizer reported additional data on PAXLOVID supporting New Drug Application submission to U.S. FDA

On Jun. 14 2022, Pfizer reported data from the Phase 2/3 EPIC-SR (Evaluation of Protease Inhibition for COVID-19…

Read More Pfizer reported additional data on PAXLOVID supporting New Drug Application submission to U.S. FDAContinue

Novavax COVID-19 vaccine Nuvaxovid provisionally registered in Australia as booster in individuals aged 18 and over
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Novavax COVID-19 vaccine Nuvaxovid provisionally registered in Australia as booster in individuals aged 18 and over

On Jun. 13 2022, Novavax announced that the Australian Therapeutic Goods Administration (TGA) had granted provisional registration of…

Read More Novavax COVID-19 vaccine Nuvaxovid provisionally registered in Australia as booster in individuals aged 18 and overContinue

Highly pathogenic avian influenza confirmed in Oregon
Agriculture | Biotechnology | Diagnostics | Infectious Disease | Influenza | USDA | Veterinary

Highly pathogenic avian influenza confirmed in Oregon

On Jun. 10, 2022, the U.S. Department of Agriculture’s (USDA) National Veterinary Services Laboratory (NVSL) confirmed the presence…

Read More Highly pathogenic avian influenza confirmed in OregonContinue

Moderna announced Omicron-containing bivalent booster candidate mRNA-1273.214 demonstrated superior antibody response against Omicron
Biotechnology | COVID-19 | Infectious Disease | Therapeutics | Vaccine

Moderna announced Omicron-containing bivalent booster candidate mRNA-1273.214 demonstrated superior antibody response against Omicron

On Jun. 8, 2022, Moderna announced new clinical data on its Omicron-containing bivalent COVID booster candidate, mRNA-1273.214, containing…

Read More Moderna announced Omicron-containing bivalent booster candidate mRNA-1273.214 demonstrated superior antibody response against OmicronContinue

Merck and Ridgeback announcd data for investigational LAGEVRIO (molnupiravir) from Phase 3 MOVe-OUT study
Biotechnology | COVID-19 | Therapeutics

Merck and Ridgeback announcd data for investigational LAGEVRIO (molnupiravir) from Phase 3 MOVe-OUT study

On Jun. 7, 2022, Merck and Ridgeback Biotherapeutics announced the Annals of Internal Medicine had published additional data…

Read More Merck and Ridgeback announcd data for investigational LAGEVRIO (molnupiravir) from Phase 3 MOVe-OUT studyContinue

Pfizer announced investment $120 million to produce COVID-19 oral treatment in the U.S.
Biotechnology | COVID-19 | Infectious Disease | Therapeutics

Pfizer announced investment $120 million to produce COVID-19 oral treatment in the U.S.

On Jun. 6, 2022, Pfizer further strengthened its commitment to United States manufacturing with a $120 million investment…

Read More Pfizer announced investment $120 million to produce COVID-19 oral treatment in the U.S.Continue

Moderna and the European Commission agreed on amendment to COVID-19 vaccine supply agreement
Biotechnology | COVID-19 | Infectious Disease | Therapeutics | Vaccine

Moderna and the European Commission agreed on amendment to COVID-19 vaccine supply agreement

On Jun. 2, 2022, Moderna announced an agreement with the European Commission (EC) to amend their originally agreed…

Read More Moderna and the European Commission agreed on amendment to COVID-19 vaccine supply agreementContinue

Novavax filed in the UK for expanded conditional Marketing Authorization of COVID-19 vaccination booster in adult
Biotechnology | COVID-19 | Vaccine

Novavax filed in the UK for expanded conditional Marketing Authorization of COVID-19 vaccination booster in adult

On Jun. 2, 2022, Novavax announced the submission of a request to the Medicines and Healthcare products Regulatory…

Read More Novavax filed in the UK for expanded conditional Marketing Authorization of COVID-19 vaccination booster in adultContinue

USDA confirmed highly pathogenic Avian influenza in Georgia
Agriculture | Biotechnology | Diagnostics | Infectious Disease | Influenza | USDA

USDA confirmed highly pathogenic Avian influenza in Georgia

On Jun. 2, 2022, the U.S. Department of Agriculture’s Animal and Plant Health Inspection Service confirmed the presence…

Read More USDA confirmed highly pathogenic Avian influenza in GeorgiaContinue

NIH study confirmed benefit of supplements for slowing age-related macular degeneration
Biotechnology | Disease | Medicine | NIH | Ophthalmogy | Therapeutics

NIH study confirmed benefit of supplements for slowing age-related macular degeneration

On Jun. 2, 2022, the National Institutes of Health (NIH) reported that the Age-Related Eye Disease Studies (AREDS…

Read More NIH study confirmed benefit of supplements for slowing age-related macular degenerationContinue

Moderna and Takeda announced plans to transfer Marketing Authorization for Spikevax(TM) COVID-19 vaccine in Japan
Biotechnology | COVID-19 | Infectious Disease | Therapeutics | Vaccine

Moderna and Takeda announced plans to transfer Marketing Authorization for Spikevax(TM) COVID-19 vaccine in Japan

On May 31, 2022, Moderna and Takeda announced the transfer of the marketing authorization for Moderna’s COVID-19 vaccine…

Read More Moderna and Takeda announced plans to transfer Marketing Authorization for Spikevax(TM) COVID-19 vaccine in JapanContinue

Novavax initiated phase 3 trial of its COVID-19 Omicron strain vaccine as a booster
Biotechnology | Infectious Disease | Vaccine

Novavax initiated phase 3 trial of its COVID-19 Omicron strain vaccine as a booster

On May 31, 2022, Novavax announced the initiation of its Phase 3 strain change trial to determine if…

Read More Novavax initiated phase 3 trial of its COVID-19 Omicron strain vaccine as a boosterContinue

Hong Kong Center for Health Protection notified late of 2nd H3N8 case on the mainland
Biotechnology | Diagnostics | Infectious Disease | Influenza | Vaccine

Hong Kong Center for Health Protection notified late of 2nd H3N8 case on the mainland

On May 30, 2022, The Centre for Health Protection (CHP) of the Department of Health received notification from…

Read More Hong Kong Center for Health Protection notified late of 2nd H3N8 case on the mainlandContinue

Wake Forest CCSG cut from 5 years to 3 as center changes leadership, administrative structure
Biotechnology | Diagnostics | Disease | Oncology | Therapeutics

Wake Forest CCSG cut from 5 years to 3 as center changes leadership, administrative structure

May 27, 2022, the National Cancer Institute (NCI) truncated the just-renewed five-year Cancer Center Support Grant held by…

Read More Wake Forest CCSG cut from 5 years to 3 as center changes leadership, administrative structureContinue

Novavax participated in Oxford University Com-COV3 booster trial of COVID-19 vaccines in adolescents aged 12 through 15
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Novavax participated in Oxford University Com-COV3 booster trial of COVID-19 vaccines in adolescents aged 12 through 15

On May 25, 2022, Novavax announced it was participating in a stage of the COVID-19 Vaccine Schedule Combinations…

Read More Novavax participated in Oxford University Com-COV3 booster trial of COVID-19 vaccines in adolescents aged 12 through 15Continue

Multi-country outbreak reported in Twelve member nations not endemic for Mpox Virus
Biotechnology | Diagnostics | Infectious Disease | Therapeutics | Vaccine | WHO

Multi-country outbreak reported in Twelve member nations not endemic for Mpox Virus

On May 21, 2022, the World Health Organization (WHO) reported that since May 13, 2022, cases of mpox…

Read More Multi-country outbreak reported in Twelve member nations not endemic for Mpox VirusContinue

Novavax filed in the EU for expanded conditional Marketing Authorization of COVID-19 vaccine as booster in individuals aged 18 and over
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Novavax filed in the EU for expanded conditional Marketing Authorization of COVID-19 vaccine as booster in individuals aged 18 and over

On May 20, 2022, Novavax announced the submission of a request to the European Medicines Agency (EMA) to…

Read More Novavax filed in the EU for expanded conditional Marketing Authorization of COVID-19 vaccine as booster in individuals aged 18 and overContinue

IAVI and Moderna launched first-in-Africa clinical trial of mRNA HIV vaccine development program
Biotechnology | HIV | Non-Profit Research | Vaccine

IAVI and Moderna launched first-in-Africa clinical trial of mRNA HIV vaccine development program

On May 18, 2022, Moderna and the nonprofit scientific research organization IAVI announced that the first participant screenings…

Read More IAVI and Moderna launched first-in-Africa clinical trial of mRNA HIV vaccine development programContinue

USDA confirmed highly pathogenic Avian influenza in New Jersey
Agriculture | Biotechnology | Diagnostics | Infectious Disease | Influenza

USDA confirmed highly pathogenic Avian influenza in New Jersey

On May 18, 2022, the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) confirmed…

Read More USDA confirmed highly pathogenic Avian influenza in New JerseyContinue

Page navigation

Previous PagePrevious 1 … 38 39 40 41 42 … 158 Next PageNext
  • Categories
  • Timeline
  • Agriculture
  • Artificial Intelligence
  • Biology
  • Biotechnology
  • Cartoons – Historical
  • Cartoons – Original
  • CDC
  • CDMO
  • Chemical
  • Cloning
  • CMO
  • COVID-19
  • CRISPR
  • CRO
  • Cryogenic
  • Dentistry
  • Diagnostics
  • Disease
  • Energy
  • Environmental
  • EPA
  • FDA
  • Forestry
  • Genomics
  • HIV
  • Infectious Disease
  • Influenza
  • IRB
  • Life Science History
  • Marine Science
  • Materials
  • Measles
  • Medical Device
  • Medicine
  • Nanotechnology
  • Neurology
  • NIH
  • Non-Profit Research
  • Nutraceuticals
  • Oncology
  • Ophthalmogy
  • Organ Transplant
  • Orthopedic
  • Other
  • Pharmaceutical
  • Plague
  • Polio
  • Prehistory
  • Radiology
  • Rare Disease
  • Stem Cell
  • Therapeutics
  • U.S. Congress
  • Uncategorized
  • USDA
  • Vaccine
  • Veterinary
  • WHO
  • Women's Health
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 2000
  • 1999
  • 1998
  • 1997
  • 1996
  • 1995
  • 1994
  • 1993
  • 1992
  • 1991
  • 1990
  • 1989
  • 1988
  • 1987
  • 1986
  • 1985
  • 1984
  • 1983
  • 1982
  • 1981
  • 1980
  • 1979
  • 1978
  • 1977
  • 1976
  • 1975
  • 1974
  • 1973
  • 1972
  • 1971
  • 1970
  • 1969
  • 1968
  • 1967
  • 1966
  • 1965
  • 1964
  • 1963
  • 1962
  • 1961
  • 1960
  • 1959
  • 1958
  • 1957
  • 1956
  • 1955
  • 1954
  • 1953
  • 1952
  • 1951
  • 1950
  • 1949
  • 1948
  • 1947
  • 1946
  • 1945
  • 1944
  • 1943
  • 1942
  • 1941
  • 1940
  • 1939
  • 1938
  • 1937
  • 1936
  • 1935
  • 1934
  • 1933
  • 1932
  • 1931
  • 1930
  • 1929
  • 1928
  • 1927
  • 1926
  • 1925
  • 1924
  • 1923
  • 1922
  • 1921
  • 1920
  • 1919
  • 1918
  • 1917
  • 1916
  • 1915
  • 1914
  • 1913
  • 1912
  • 1911
  • 1910
  • 1909
  • 1908
  • 1907
  • 1906
  • 1905
  • 1904
  • 1903
  • 1902
  • 1901
  • 1900
  • 1899
  • 1898
  • 1897
  • 1896
  • 1895
  • 1894
  • 1893
  • 1892
  • 1891
  • 1890
  • 1889
  • 1888
  • 1887
  • 1886
  • 1885
  • 1884
  • 1883
  • 1882
  • 1881
  • 1880
  • 1879
  • 1878
  • 1877
  • 1876
  • 1875
  • 1874
  • 1873
  • 1872
  • 1871
  • 1870
  • 1869
  • 1868
  • 1867
  • 1866
  • 1865
  • 1864
  • 1863
  • 1862
  • 1861
  • 1860
  • 1859
  • 1858
  • 1857
  • 1856
  • 1855
  • 1854
  • 1853
  • 1852
  • 1851
  • 1850
  • 1849
  • 1848
  • 1847
  • 1846
  • 1845
  • 1844
  • 1843
  • 1842
  • 1840
  • 1839
  • 1838
  • 1837
  • 1836
  • 1834
  • 1833
  • 1832
  • 1831
  • 1830
  • 1828
  • 1827
  • 1826
  • 1825
  • 1824
  • 1823
  • 1820
  • 1819
  • 1818
  • 1817
  • 1816
  • 1813
  • 1811
  • 1810
  • 1809
  • 1808
  • 1804
  • 1802
  • 1801
  • 1800
  • 1799
  • 1798
  • 1796
  • 1795
  • 1794
  • 1793
  • 1790
  • 1789
  • 1788
  • 1786
  • 1785
  • 1784
  • 1782
  • 1781
  • 1777
  • 1769
  • 1765
  • 1761
  • 1753
  • 1751
  • 1749
  • 1747
  • 1746
  • 1743
  • 1741
  • 1738
  • 1727
  • 1723
  • 1721
  • 1720
  • 1718
  • 1716
  • 1712
  • 1697
  • 1693
  • 1683
  • 1674
  • 1667
  • 1666
  • 1665
  • 1664
  • 1663
  • 1658
  • 1656
  • 1647
  • 1636
  • 1634
  • 1629
  • 1621
  • 1603
  • 1580
  • 1521
  • 1510
  • 1403
  • 1377
  • 1370
  • 1363
  • 1348
  • 1346
  • 1322
  • 1285
  • 1202
  • 1200
  • 1179
  • 1100
  • 1050
  • 541
  • 470
  • 1
Subscribe to E-History

Subscribe

* indicates required

LifeScienceHistory.com

LifeScienceHistory.com Where history is made daily, is a comprehensive companion of life science. Simply put, we dig history and we mine data.

More

  • About
  • Life Science Heroes

Advertising

  • Life Science Banner Advertising
  • Advertise Your Life Science Jobs

Legal

  • Privacy Policy
  • Terms of Use

© 2025 LifeScienceHistory.com by James Web Design

Facebook Instagram Linkedin
  • Home
  • Directory
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • Careers
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a Rock
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
Search